Adherence Preparing to start ARVs

1. Adherence Preparing to start ARVs Dr. Kevin M Harvey MBBS, MPH (UWI), Dip. ID (Lon.) Treatment care and support 2006

2. What do we know?:HIV Treatment in 2004 • Many regimens are active in people with no drug resistance • Measured as suppression of virus (lowering plasma viral load to under detection) or other response to treatment (CD4, clinical, weight etc) • But treatment after resistance develops is still a challenge and usually requires more complicated and/or more expensive regimens • In addition resistant virus can be transmitted • Failure carries a high price on an individual, financial and public health • Finding the reasons and preventing failure is therefor critical

3. Why does antiretroviral therapy fail? • Not a cure • Efficacy • Drug toxicity • Drug interactions • Drug resistance • Adherence issues – lifelong therapy • Cost

4. Failure of Therapy: Types of failure • Clinical failure Progression of disease, new infections • Immunologic failure Decline in CD4 count • Virologic failure Persistent viral replication (usually associated with resistance) • Drug toxicity Severe side effects • Infrastructure failure Lack of drug supply, lack of money to pay for drugs

5. ART in the “Real” World • Many clinical trials show suppression of virus in >80% of subjects • BUT, studies in a multitude of clinical settings have shown only 50-70% success rates with multiple-drug therapy at 1-2 years • WHY? • While baseline resistance and poor prescribing contribute, poor adherence accounts for many of these failures* • As HIV turns from a uniformly fatal illness to a chronic disease, adherence grows even more important *Estimates from 40-80% report some non-adherence

6. Adherence • Adherence • Compliance • Concordance • Taking the medication/following the regimen as directed (dose, timing, diet etc etc) with follow-up and care as directed • WHO: the extent to which a person’s behaviour – taking medication, following a diet,and/or executing lifestyle changes, corresponds with agreed recommendations from a health care provider.

7. Adherence in other diseases* • Poor adherence to treatment of chronic diseases is a worldwide problem of striking magnitude • Average of 50% in most diseases • Ex. Non-adherence accounts for a significant percent of admissions in patients with heart failure • The consequences of poor adherence to long-term therapies are poor health outcomes and increased health care costs • Increasing the effectiveness of adherence interventions may have a far greater impact on the health of the population than any improvement in specific medical treatments • A multidisciplinary approach towards adherence is needed *WHO. Adherence to long-term therapies: evidence for action, 2003.

8. WHO. Adherence to long-term therapies: evidence for action • Adherence is simultaneously influenced by several factors Factors include: • Medication • Ex. Dose frequency, side effects • Patient • ex. Readiness, substance use • Health care system/providers • Ex. Patient provider relationship • Treatment education • DOT • cost • Community/environment • Ex. Stigma, transport • Adherence is a dynamic process that needs to be followed up • Improving long-term adherence is complex and required continuous support and monitoring • Health professionals need to be trained in adherence • Family, community and patients’ organizations: a key factor for success in improving adherence

9. Why is HIV different • Excellent adherence in other diseases is considered >60-70% • Adherence rates for HIV need to be higher • >95% • Non adherence with HIV carries very high risk of virus developing drug resistance • Once resistance develops, that drug (and possibly others) will never work as well or may not work at all • Communicable disease

10. Adherence and viral suppression Percentage of Medication Taken <80% 100% 80% to 95% 95% to 99% 50 Percent of patients with viral load <500 copies 40 30 20 10 0 2 Months 6 Months Haubrich RH, et al. AIDS 1999;13:1099-107.

11. HIV, adherence and clinical significance • Better adherence is also linked with decreased risk of getter sicker from HIV infection, losing more CD4 cells, and dying from HIV

12. Adherence in resource richer areas • Average rates of adherence vary widely, but generally fall well short • Percentage of patients with treatment failure in clinical practice reflect a combination of non adherence and resistance: • USA 50% • Amsterdam 40% • Swiss • naïve 38% • experienced 70% • Johns Hopkins 63% • Cleveland 53%

13. Adherence to ARVs treatment over time Percent reporting 100% adherence *p<0.01 for difference between months 1 & 4 and months 1 & 8 Mannheimer et al, CPCRA, 2000.

14. Adherence in Resource-limited settings • In programs with self-pay, cost is not always the major barrier to adherence • Innovative approaches to support adherence before and during treatment are being used

15. Adherence to ARVs in resource-limited settings:* • Uganda: 88% • Cote d’Ivoire: 75% • Haiti: 88% • Senegal: 78%-88% • South Africa: 89% • Brazil: range: 57%-87% • Botswana: ~55% • Nigeria: 58% • Kenya: 59% Adherence is as problematic in resource-limited settings as it is in resource-rich settings. No evidence to show that it is more problematic. * NB: small studies, differing definitions of adherence

16. Adherence in resource limited settings • African Countries • Strong pre treatment education and screening, counselors and treatment buddy • High rates of adherence, viral suppression • Need to determine critical components for scale-up Cootzee, AIDS 18 suppl 3, 2004

17. Predictors of nonadherence: Medication related • dosing frequency • side effects • Number of pills • ?type of medication • ?complexity of regimen

18. Patient-related • Active substance abuse • Depression • HIV knowledge and knowledge and belief in medications • Literacy (?more of a system problem) • Non-adherence to care • Stage of readiness • ?Distance from site • ?age • ?disclosure

19. System-related • Cost of care/treatment • Access to care and medications • provider/patient relationship • Stock-outs • ?employment out of the home • ?transportation • ?stigma

20. Non-predictors • Non-predictors include • Race • gender • prior substance abuse • social status or income • education

21. Other reasons people do not take their ART • Pill fatigue • Forgot • Pills not with them • Transportation • Fear of disclosure • Concern with drug interactions (prescribed or other) • And others

22. Preparing for Adherence • More sustainable response to ARVs if adherence is optimized within the first three to six months • Must therefore prepare individuals to adhere prior to the start of ARVS • Must also have a strategy to sustain adherence throughout life

23. Preparing for ARVs • Culture • Access +Knowledge + Motivation+Cues to Action • Stigma & Discrimination • ADHERENCE

24. Potential Barriers Distance from Clinic Appointment system User Fees Availability of Service Confidentiality Stigma & Discrimination Cost for CD4,Viral Loads + other labs Cost of other Medicines Cultural Practices Possible Solutions Telephone Appointments Waiver from User Fees (free does not =Access) Waiver from General fees & lab cost via assessment Process Refer closest acceptable Treatment site Assistant with Bus Fares Register with the NHF Family support Access

25. Potential Barriers Believes Culture Myths Low literacy Lack of Exposure to Specific HIV Education Educational Material inappropriate Possible Solutions Appropriate Literacy Material for Individual HIV Basic Facts Condom Negotiation Skills Name etc of Specific Meds Knowledge

26. Potential Barriers Depression Number of pills Frequency of doses per day No Family support No disclosure /fear disclosure Negligence/ forgetfulness Unemployment Lack of privacy Possible Solutions Refer to Social Worker Mental Health Professional Reduce the number of pills If possible link meds to something the patient does that they enjoy Refer to support groups Encourage disclosure, provide temporary support encourage buddy system Channel to income generating projects Motivation

27. Barriers Non Disclosure and lack of support Drug addiction Stigma and Discrimination Attention drawn by Reminders Pill boxes can be too big Late refills Cognitive function Possible Solutions Family Support Media Pill Boxes Text Messages Alarms Link to Favourite radio and TV programmes Support at workplace Cues to Action

28. Barriers Patients only listen to doctor Alternative Medicine Can provide a Cure Role of the Church Myths Solutions Patients will listen to Doctors Alternative(Herbal Medicines) can be immune boosters Education of Clergy Culture

29. Potential Barriers Fear Discrimination Lack of or Low Public education Remove Labels Fail to take meds in Public Move away from district Do not want to attend Clinic in Own district Visible side effects Possible Solutions Confidentiality at the work place is key Reduced stigma and discrimination at work place Refer to acceptable treatment site or facilitate easier access Stigma & Discrimination

30. Supportive Environment • Knowledge Motivation • Positive Behaviour Change • Increased Adherence

31. Family-Focused Adherence Support • It may take several weeks and several visits to ready the family for treatment. • Before prescribing • Family is part of and agrees with treatment plan • Assess family life-style, priorities, beliefs • Ask about prior medication experience: build on success and work on problems • Educate about the disease, purpose of ARV, importance of adherence • Repeat information as many times as necessary

32. Family-Focused Adherence Support • Planning for a good start: • Develop a simple schedule that fits the family’s daily activities. Consider differences between weekdays and weekends. • Clarify who will be responsible for giving or supervising each dose, each day of the week • Make the schedule visual. Use pictures of pills. Color-code everything. Consider literacy level of family members

33. Family-Focused Adherence Support • Planning for a good start: • Demonstrate medication preparation: • measuring volumes of liquids • crushing or dissolving tablets • opening capsules • using foods or liquids to mask task • Do a trial run with “dummy” pills or liquid • Observe medication administration in the office. If possible, start the first dose under supervision • Follow-up with a phone call and/or home visit in the first few days

34. General lessons we have learned • Adherence is hard for everyone and long term treatment present the most difficult challenges • Adherence is critical to the successful care of patients with HIV/AIDS • On an individual level, adherence to care and treatment can mean the difference between life and death • On a population level, adherence to treatment can minimize the emergence of viral resistance and prevent therapeutic failure • Adherence needs to be to medications and care.

35. More lessons • Every HIV/AIDS treatment program should include processes to assess and support adherence • Adherence promotion must be multifaceted and multidisciplinary and adapt to changing needs and realities • Many models/approaches in use • Many also need to be evaluated and adapted for local needs • Simpler and more tolerable regimens which preserve efficacy are still needed

36. Acknowledgements • Sources for some of the slides or materials included: • KITSO AIDS Training Program (Botswana) • MTCT-Plus training (Columbia University) • Vietnam-CDC-Harvard Medical School AIDS Partnership (VCHAP) • Colleagues and most importantly,people living with HIV